Modelling protective anti-tumour immunity using a hybrid agent-based
and delay differential equation approach

Although cancers seem to consistently evade current medical
treatments, the body's immune defences seem quite effective at
controlling incipient tumours.  Understanding how our immune systems
provide such protection against early-stage tumours and how this
protection could be lost will provide insight into designing
next-generation immune therapies against cancer.  To engage this
problem, we formulate a mathematical model of the immune response
against small, incipient tumours.  The model considers the initial
stimulation of the immune response in lymph nodes and the resulting
immune attack on the tumour and is formulated as a hybrid agent-based
and delay differential equation model..